November 25, 2019
2 min watch
Save
VIDEO: New agent reduces hyperemia in dry eye disease
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
ORLANDO, Fla. – Kala Pharmaceuticals’ KPI-121 0.25% significantly and rapidly reduced conjunctival hyperemia in three clinical trials, Walt Whitley, OD, said here at the American Academy of Optometry meeting.
More than 1,900 patients were enrolled, and they experienced no adverse events, he said.
Disclosure: Whitley reports he is a consultant for Kala.